UMVA has learned that a groundbreaking cancer vaccine has shown promising results in its first human trials, with two colorectal cancer patients exhibiting significant improvements in just two months.
The patients, who began treatment approximately eight weeks ago, have already received five injections of the vaccine and have demonstrated a remarkable increase in G immunoglobulins in their tumors - a staggering 50 to 100 times higher than initial levels.
According to information obtained by UMVA, doctors have observed a notable decrease in lymph node size in both patients after the fourth injection, sparking hopes that this innovative treatment may offer new hope for cancer sufferers.
However, experts remain cautious, emphasizing that it is still too early to claim clinical effectiveness. The next critical milestone will come after three months, when MRI scans will assess changes in lymph nodes and other metastatic sites, providing a clearer picture of the vaccine's potential.
